Real-World Patterns of Step-Up Dosing Period and Early Safety Outcomes in US Patients Treated With Teclistamab for Multiple Myeloma

被引：0

作者：

Rahul, Banerjee ^{[1
]}

Hsien-Yen, Chang ^{[2
]}

Dee, Lin ^{[2
]}

Alex, Fu Z. ^{[2
,3
]}

Laura, Hester ^{[4
]}

Nina, Kim ^{[2
]}

Jessica, Fowler ^{[5
]}

Sian, Walker ^{[6
]}

Dina, Gifkins ^{[4
]}

Christina, Hearty ^{[2
]}

Wu Bingcao ^{[2
]}

机构：

[1] Fred Hutchinson Canc Ctr, Seattle, WA USA

[2] Janssen Sci Affairs, Titusville, NJ USA

[3] Georgetown Univ, Med Ctr, Washington, DC 20007 USA

[4] Janssen R&D LLC, Raritan, NJ USA

[5] Janssen US Med Affairs, Horsham, PA USA

[6] Sierra Med Affairs LLC, Truckee, CA USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P-045

引用

页码：S28 / S29

页数：2

共 50 条

[21] Real-world treatment patterns and outcomes in lenalidomide refractory multiple myeloma patients in Europe: a real-world survey
Martinez-Lopez, Joaquin
Mendes, Joao
Luke, Emily
Kluth, Caspian
Salmon, Phoebe
Bailey, Abigail
Ribbands, Amanda
Gay, Francesca
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S198 - S199
[22] Teclistamab in Relapsed/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest
Stepanovic, Adam
Abonour, Rafat
Abu Zaid, Mohammad
Farag, Sherif
Lee, Kelvin P.
Suvannasankha, Attaya
BLOOD, 2023, 142
[23] Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States
Varughese, Prateesh
Smith, Robert
Xue, Mei
Dorrow, Natalie
Hogea, Cosmina
Maiese, Eric. M.
Buckingham, Trudy
EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (01) : 65 - 74
[24] Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
Mian, Hira
Tan, Carlyn Rose
Asoori, Sireesha
Popat, Rakesh
Abdallah, Nadine
Chhabra, Saurabh
Parrondo, Ricardo D.
Pond, Gregory R.
Martin, Thomas
Durie, Brian G. M.
Lin, Yi
BLOOD, 2024, 144 : 704 - 705
[25] Current Real-World Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma
Willson, Jenny
Bruno, Amanda
Opalinska, Joanna
Nelson, Jeannene
Lunacsek, Orsolya
Stafkey-Mailey, Dana
Willey, Joanne
BLOOD, 2018, 132
[26] Real-World Treatment Patterns and Outcomes of Patients with Functional High-Risk (Early Relapse) Multiple Myeloma
Belli, Andrew J.
Hansen, Eric
Kansagra, Ankit
Dilwali, Keshava
Wang, Ching-Kun
BLOOD, 2020, 136
[27] Real-world treatment patterns of adult multiple myeloma patients treated with carfilzomib in the US community oncology setting.
Panjabi, Sumeet
Medhekar, Rohan
Aguilar, Kathleen
Wilson, Thomas
Amirian, E. Susan
Mezzi, Khalid
Rifkin, Robert M.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
Samlowski, Wolfram
Robert, Nicholas J.
Chen, Liwei
Schenkel, Brad
Davis, Catherine
Moshyk, Andriy
Kotapati, Srividya
Poretta, Tayla
Weber, Jeffrey S.
CANCER MEDICINE, 2023, 12 (03): : 2378 - 2388
[29] Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma
Tan, Carlyn Rose Co
Derkach, Andriy
Maclachlan, Kylee
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Rajeeve, Sridevi
Shah, Gunjan L.
Scordo, Michael
Chung, David J.
Landau, Heather Jolie
Giralt, Sergio
Lesokhin, Alexander M.
Korde, Neha
Lin, Dee
Wu, Bingcao
Fowler, Jessica
Fernandez, Mariana
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[30] DURATION OF THERAPY IN US PATIENTS TREATED FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE REAL-WORLD
Romanus, D.
Raju, A.
Yong, C.
Seal, B.
Farrelly, E.
Noga, S.
Jhaveri, M.
Labotka, R.
Blazer, M.
Parameswaran, H.
HAEMATOLOGICA, 2016, 101 : 538 - 539

← 1 2 3 4 5 →